Biologics Contract Development and Manufacturing Organizations (CDMOs) have emerged as pivotal players in the dynamic landscape of the global pharmaceutical industry. Fueled by rapid advancements in biotechnology, these specialized entities offer end-to-end solutions, from development to manufacturing, for biopharmaceutical products. With the global market projected to reach an impressive $27 billion by the end of 2028, Biologics CDMOs play a critical role in accelerating the production of cutting-edge therapies, fostering innovation, and meeting the increasing demand for complex biological drugs. This short introduction sets the stage for exploring the transformative impact of Biologics CDMOs on the world stage, as they navigate the challenges and opportunities within this lucrative and ever-evolving market.
BOSTON, Jan. 5, 2024 /PRNewswire/ — According to the latest research study, the demand for Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets is expected to increase from $15.1 billion in 2023 to $27.0 billion by the end of 2028, at a compound annual growth rate (CAGR) of 12.3% during the forecast period 2023-2028.
This comprehensive report delves into various aspects of biologics CDMO, encompassing services, industries, initiatives, patents, and companies. It outlines the market trends for biologics CDMO across the years 2020, 2021, 2022, 2023, and 2028. Providing valuable insights, the report elucidates the crucial role of biologics CDMO in the pharmaceutical and biotechnology sectors. Furthermore, it sheds light on impactful research initiatives influencing biologics CDMO and analyzes the primary market-driving forces. To offer a detailed perspective, the report scrutinizes the markets based on product type, cell line type, and region. It presents market data and forecasts specifically for biologics CDMO, distinguishing between biologics and biosimilars. The geographical focus includes North America, Europe, Asia-Pacific, and the Rest of the World (RoW), contributing to a comprehensive understanding of the industry landscape./.
The integration of Artificial Intelligence (AI), Machine Learning (ML), and big data in CDMO (Contract Development and Manufacturing Organization) companies is becoming increasingly essential due to the growing demand for quick and accurate results. Lonza, for instance, utilizes these technologies in its R&D teams to facilitate tasks like computer-aided drug design, protein profile assessment, engineering mammalian expression systems, and predicting side effects for novel therapies. Market players are intensifying their research and development efforts to introduce innovative products. Additionally, the implementation of Process Analytical Technology (PAT) in chemical processes, exemplified by Lonza Group, enhances efficiency and product quality through real-time monitoring and management. This technology ensures consistent production of biologic APIs meeting specified quality standards. Companies like Novartis are actively exploring new technologies to address challenges in the industrialization of cell and gene therapies. The rising demand for biologics, especially for treating chronic diseases and autoimmune conditions, is fueling the need for biologics CDMO services, underlining the evolving landscape of pharmaceutical solutions.
Driving forces behind the biologics contract development and manufacturing organizations (CDMOs): global market’s insights growth comprises:
- Rising Prevalence of Cancer- The rising prevalence of cancer is a global health concern characterized by the uncontrolled growth of abnormal cells that can invade and spread to other parts of the body. Cancer can affect virtually any organ or tissue and is a leading cause of morbidity and mortality worldwide. Factors contributing to the increasing incidence of cancer include aging populations, lifestyle choices such as smoking and poor diet, environmental exposures, and genetic predisposition. Early detection and advancements in cancer treatments, including surgery, chemotherapy, radiation therapy, and immunotherapy, play crucial roles in improving outcomes. Public health efforts emphasize preventive measures, awareness campaigns, and ongoing research to better understand and combat the complexities of cancer, highlighting the importance of a comprehensive and multi-faceted approach to address this pervasive health challenge.
- Increasing Demand for Biologics- The increasing demand for biologics reflects a growing preference for therapeutic products derived from living organisms, such as proteins, antibodies, and vaccines. Biologics offer innovative treatment options for various medical conditions, including autoimmune disorders, cancer, and chronic diseases. Their popularity stems from their ability to target specific disease pathways with greater precision, potentially leading to enhanced efficacy and fewer side effects compared to traditional pharmaceuticals. The rise in demand is also driven by advancements in biotechnology, enabling the development of more complex and personalized biologic therapies. As the pharmaceutical industry continues to invest in research and development, the expanding role of biologics in healthcare is expected to reshape treatment landscapes and contribute to the evolution of personalized medicine.
- Rising Use of CDMOs– The rising use of Contract Development and Manufacturing Organizations (CDMOs) signifies a notable trend in the pharmaceutical and biotechnology industries. Companies increasingly turn to CDMOs for specialized services in drug development and manufacturing, allowing them to focus on core competencies while leveraging external expertise. CDMOs provide a range of services, including research and development, formulation, analytical testing, and large-scale manufacturing of pharmaceutical products. This outsourcing model offers flexibility, cost-efficiency, and accelerated timelines in bringing new drugs to market. The trend is fueled by the complexity of drug development, regulatory requirements, and the need for specialized technologies and facilities. As the demand for innovative therapies continues to grow, the role of CDMOs is likely to expand, playing a pivotal role in the efficient and timely delivery of pharmaceutical products to meet global healthcare needs.
- Increasing Elderly Population- The increasing elderly population is a prominent demographic shift worldwide, marked by a rise in the number and proportion of people aged 65 and older. This trend is largely attributed to factors such as longer life expectancies and declining birth rates. The aging population poses various societal and healthcare challenges, including an increased demand for healthcare services, long-term care, and age-related medical treatments. It also influences economic dynamics, pension systems, and social structures. As countries grapple with the implications of this demographic shift, there is a growing focus on developing policies and healthcare strategies to address the specific needs of the elderly, promote healthy aging, and ensure adequate support for aging individuals in areas such as healthcare, housing, and social services. The trend underscores the importance of adapting societal structures and healthcare systems to meet the evolving needs of an aging population.
Request a Copy of the Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets
Report Synopsis
|
Report Metrics |
Details |
|
Base year considered |
2022 |
|
Forecast Period considered |
2023-2028 |
|
Base year market size |
$13.4 billion |
|
Market Size Forecast |
$27.0 billion |
|
Growth Rate |
CAGR of 12.3% for the forecast period of 2023-2028 |
|
Segment Covered |
Product Type, Cell Line Type |
|
Regions covered |
North America, Europe, Asia-Pacific, Rest of the World (RoW) |
|
Countries covered |
U.S., Canada, Germany, France, U.K., Italy, Spain, Rest of Europe, China, India, Japan, South Korea, Australia, Rest of Asia-Pacific |
|
Key Market Drivers |
|
The Rising Demand for Biologics Contract Development and Manufacturing Organizations (CDMOs): Global Markets:
The increasing demand for Biologics Contract Development and Manufacturing Organizations (CDMOs) reflects a dynamic global market characterized by a growing reliance on specialized outsourcing services in the biopharmaceutical industry. Biologics, including therapeutic proteins, monoclonal antibodies, and gene therapies, are gaining prominence in treating various diseases. As pharmaceutical and biotechnology companies seek efficient and cost-effective solutions, they turn to CDMOs to navigate the complexities of biologics development and production. This trend is driven by the need for specialized expertise, state-of-the-art facilities, and flexibility in manufacturing capacities. The global market for Biologics CDMOs is experiencing substantial growth, influenced by factors such as advancements in biotechnology, an expanding pipeline of biologics, and a focus on personalized medicine. As these trends persist, the role of Biologics CDMOs is poised to become increasingly pivotal in the swift and successful delivery of biopharmaceutical products to meet global healthcare demands.
Trends and Innovations:
The landscape for Biologics Contract Development and Manufacturing Organizations (CDMOs) is marked by dynamic trends and continuous innovations, shaping the global markets in significant ways. A notable trend is the increasing collaboration between pharmaceutical and biotechnology companies and specialized CDMOs to navigate the complexities of biologics development. This collaboration facilitates access to cutting-edge technologies and expertise, enabling efficient and cost-effective solutions in an evolving biopharmaceutical industry. Innovations in bioprocessing technologies, including single-use systems and continuous manufacturing, contribute to enhanced flexibility and scalability in production, meeting the demands of a diverse and expanding pipeline of biologics. Additionally, there is a growing emphasis on digitalization and data analytics to optimize manufacturing processes, ensuring higher quality and compliance. As the demand for personalized medicine rises, CDMOs play a pivotal role in tailoring biologics to specific patient needs. Overall, the trends and innovations in the Biologics CDMO sector underscore a dynamic and forward-thinking approach to meet the evolving demands of the global healthcare market.
Challenges and Opportunities:
Biologics Contract Development and Manufacturing Organizations (CDMOs) face a set of challenges and opportunities within the global markets. Challenges include the inherent complexity of biologics production, which demands sophisticated manufacturing capabilities and stringent quality control measures. Regulatory compliance is another hurdle, given the evolving nature of biopharmaceutical regulations globally. Additionally, the competitive landscape is intensifying, prompting CDMOs to differentiate themselves through technological innovation and strategic partnerships. However, these challenges also present opportunities. With the increasing demand for biologics, CDMOs have the chance to expand their market presence and explore novel therapies, fostering innovation in manufacturing processes. Collaborations with academic institutions and biotech firms offer opportunities for research and development, enhancing CDMOs’ expertise. Moreover, the trend towards personalized medicine opens avenues for CDMOs to tailor biologics to specific patient populations. Successfully navigating these challenges and capitalizing on opportunities positions Biologics CDMOs to play a pivotal role in advancing the global biopharmaceutical industry.
This report on the biologics contract development and manufacturing organizations (CDMOs): global markets insights provide comprehensive insights and analysis, addressing the following key questions:
- What is the anticipated market scale and rate of expansion?
Forecasts indicate that the biologics CDMOs market is expected to increase from $13.4 billion in 2022 to $27.0 billion in 2028, reflecting a compound annual growth rate (CAGR) of 12.3% throughout the projected period.
- What factors are propelling the market’s expansion?
The growth of the biologics CDMO market is propelled by several key factors, including a growing elderly population, heightened demand for biologicals, and substantial investments in healthcare infrastructure, all contributing to the market’s upward trajectory.
- Which categories are included in the market analysis?
The market analysis for biologics CDMOs is divided into segments based on product type, cell line type, and geographical regions.
- Which segment is expected to lead the market by the conclusion of 2028 in terms of cell line type?
The mammalian segment is projected to be the dominant force in the biologics CDMO market by the end of 2028.
- Which region has the highest market share in the market?
North America holds the highest share of the market.
Some of the Key Market Players Are:
- ABBVIE PHARMACEUTICAL CONTRACT MANUFACTURING
- AGC BIOLOGICS
- BOEHRINGER INGELHEIM BIOXCELLENCE
- BINEX CO. LTD.
- BIOVIAN OY
- BORA PHARMACEUTICAL CDMO
- CATALENT INC
- CYTOVANCE BIOLOGICS
- EMERGENT BIOSERVICES
- FUJIFILM DIOSYNTH BIOTECHNOLOGIES
- ICON PLC
- JRS PHARMA GMBH & CO. KG
- KEMWELL
- LONZA GROUP
- LOTTE BIOLOGICS
- PAREXEL INTERNATIONAL CORP.
- RENTSCHLER BIOPHARMA SE
- SAMSUNG BIOLOGICS
- SANDOZ INTERNATIONAL GMBH
- THERMO FISHER SCIENTIFIC INC.
- TOYOBO CO. LTD.
- WUXI XDC
Browse More Related Reports:
Global Market Opportunities and Competitive Landscape for CDMO: Navigating the dynamic landscape of Contract Development and Manufacturing Organizations (CDMOs) presents a myriad of global market opportunities and a complex competitive landscape. This sector, vital to the pharmaceutical and biotechnology industries, is marked by evolving trends, technological innovations, and increasing demand. As companies seek external expertise for efficient and specialized services, the competitive arena for CDMOs becomes multifaceted. This introduction sets the stage to explore the diverse opportunities and competitive dynamics shaping the CDMO landscape on a global scale.
Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Delving into the expansive realm of Contract Pharmaceutical Manufacturing, Research, and Packaging unveils a world of global markets brimming with opportunities and intricacies. This multifaceted sector plays a pivotal role in the pharmaceutical industry, offering diverse services that encompass manufacturing, research, and packaging. As pharmaceutical companies increasingly leverage external collaborations for efficiency and specialization, the competitive landscape within this global arena becomes both dynamic and complex. This introduction sets the groundwork for an exploration of the vast opportunities and competitive dynamics that define the global markets for contract pharmaceutical services and underscores the industry’s ever-evolving nature.
Directly Purchase a copy of the report with BCC Research.
For further information or to make a purchase, please get in touch with [email protected].
About BCC Research
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts’ goal is to help you make informed business decisions, free of noise and hype.
Contact Us
Corporate HQ:
BCC Research LLC
49 Walnut Park, Building 2
Wellesley, MA 02481, USA
[email protected],
+1 781-489-7301
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email [email protected] or visit www.bccresearch.com/media to request access to our library of market research.
Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
SOURCE BCC Research LLC
